Anti-CD19 CAR T-Cell Therapy Effective in Relapsed/Refractory B-Cell Acute Lymphocytic Leukemia
Investigators aimed to determine and compare outcomes in patients with relapsed or refractory ALL who were treated with anti-CD19 CAR T-cell therapy.
Diagnosis & Disease Information
BCMA-Directed CAR T-Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Opposition to a European Patent for CAR-T Therapy: A Mechanism to Control High Drug Prices?
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
Characterization of Neurotoxicity After CAR-T in LBCL
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
G-CSF Appears Safe in CAR-T–Treated Patients With Refractory/Relapsed B-Cell Lymphoma
The treatment reduced hospital stay but not neutropenia duration or infection rate.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...